IGC Phase 1 trial for THC-based Alzheimer's drug IGC-AD1 shows statistically significant NPI reductions; no SAEs

IGC Pharma, Inc.

Mean NPI decreased from baseline 31.5 to 16.7 on day 10 (p=0.0044) in Cohort 1; improvements in agitation, anxiety, appetite disorders.
No serious adverse events or deaths across all cohorts; only one related AE (mild dizziness) reported.
IGC plans to design a larger multi-site Phase 2/3 trial pending FDA approval for IGC-AD1.
Sixty-two percent of participants had CYP2C9 intermediate metabolizer phenotype, affecting THC half-life (5.09 h vs 1.73 h for normal).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.